Molecular genetic alterations in glioblastomas with oligodendroglial component.

作者: Jürgen A. Kraus , Katrin Lamszus , Nicole Glesmann , Martina Beck , Marietta Wolter

DOI: 10.1007/S004010000258

关键词: BiologyChromosomeCancer researchPTENEpidermal growth factor receptorCDKN2AGrowth factor receptorEpidermal growth factorLoss of heterozygosityMutation

摘要: Glioblastoma multiforme is the most malignant astrocytic glioma and usually resistant to chemotherapy. A small fraction of glioblastomas may contain areas with histological features oligodendroglial differentiation. To determine molecular genetic alterations in such "glioblastomas component", we investigated 13 these tumors for and/or expression TP53, CDKN2A, PTEN, EGFR genes. In addition, performed microsatellite analyses loss heterozygosity (LOH) on chromosome arms 1p, 19q 10q. None showed evidence LOH 1p was detected 3 tumors, 1 which additionally 19q. The neither TP53 mutations nor nuclear p53 accumulation. contrast, 9 10 without demonstrated losses were identified cases. Further aberrations epidermal growth factor receptor (EGFR) overexpression (3 tumors), homozygous CDKN2A deletion (2 11 PTEN mutation (1 tumors). Taken together, our results indicate that component" carry heterogeneous alterations. 10q, mutation, appear be less common as compared ordinary glioblastomas. Furthermore, a subset demonstrates i.e., an alteration has recently been linked chemosensitivity good prognosis anaplastic oligodendrogliomas.

参考文章(40)
ED Harlow, David Lane, A Laboratory manual Cold Spring Harbor Laboratory. ,(1989)
G Reifenberger, K Ichimura, V P Collins, E E Schmidt, CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Research. ,vol. 54, pp. 6321- 6324 ,(1994)
Carolyn A. Pedone, Dan Fults, Ray White, Ray White, Gregory A. Thomas, Allelotype of human malignant astrocytoma. Cancer Research. ,vol. 50, pp. 5784- 5789 ,(1990)
Peter C. Burger, Bernd W. Scheithauer, Tumors of the Central Nervous System ,(2007)
Guido Reifenberger, Ghazaleh Tabatabai, Marietta Wolter, J. M. J. Ludwig Cobbers, V. Peter Collins, Peter Lichter, Ruthild G. Weber, Jan Boström, Mutation of the PTEN (MMAC1) Tumor Suppressor Gene in a Subset of Glioblastomas but not in Meningiomas with Loss of Chromosome Arm 10q Cancer Research. ,vol. 58, pp. 29- 33 ,(1998)
G Cairncross, D Macdonald, S Ludwin, D Lee, T Cascino, J Buckner, D Fulton, E Dropcho, D Stewart, C Schold, Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. ,vol. 12, pp. 2013- 2021 ,(1994) , 10.1200/JCO.1994.12.10.2013
Michael D. Taylor, James Perry, Magdalena C. Ƶlatescu, Anat O. Stemmer-Rachamimov, L. C. Ang, Yasushi Ino, Michael Schwartz, Laurence E. Becker, David N. Louis, J. Gregory Cairncross, The hPMS2 exon 5 mutation and malignant glioma. Case report. Journal of Neurosurgery. ,vol. 90, pp. 946- 950 ,(1999) , 10.3171/JNS.1999.90.5.0946
Tetsuro Sano, Huai Lin, Xiashan Chen, Lauren A Langford, Dimpy Koul, Melissa L Bondy, Kenneth R Hess, Jeffrey N Myers, Yong-Kil Hong, WK Alfred Yung, Peter A Steck, None, Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Research. ,vol. 59, pp. 1820- 1824 ,(1999)
W Wechsler, L Liu, L Liu, G Reifenberger, G Reifenberger, J Reifenberger, C D James, V P Collins, V P Collins, Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. American Journal of Pathology. ,vol. 145, pp. 1175- 1190 ,(1994)
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277